These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12635469)

  • 21. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.
    Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
    Fundam Clin Pharmacol; 2009 Oct; 23(5):595-600. PubMed ID: 19563510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atherogenic lipid profiles in rheumatoid arthritis.
    White D; Fayez S; Doube A
    N Z Med J; 2006 Aug; 119(1240):U2125. PubMed ID: 16924276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
    Cuchacovich M; Ferreira L; Aliste M; Soto L; Cuenca J; Cruzat A; Gatica H; Schiattino I; Pérez C; Aguirre A; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2004; 33(4):228-32. PubMed ID: 15370717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
    Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE; Oustamanolakis P; Malliaraki N; Karmiris K; Chalkiadakis I; Ganotakis E; Karkavitsas N; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
    Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
    Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
    Sachdeva A; Cannon CP; Deedwania PC; Labresh KA; Smith SC; Dai D; Hernandez A; Fonarow GC
    Am Heart J; 2009 Jan; 157(1):111-117.e2. PubMed ID: 19081406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
    Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
    Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients.
    Castro KR; Aikawa NE; Saad CG; Moraes JC; Medeiros AC; Mota LM; Silva CA; Bonfá E; Carvalho JF
    Clin Dev Immunol; 2011; 2011():352686. PubMed ID: 21804855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.